Drug Trial Radar · NCT07111546
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 20, 2025
Primary completion
Dec 26, 2027
Study completion Dec 26, 2027
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Zhongshan Hospital
- First posted
- Aug 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
Conditions
- Advanced Solid Tumour
Interventions
LBL-024 for InjectionDrug
Intravenous infusion.
Cisplatin InjectionDrug
Intravenous infusion.
Gemcitabine Hydrochloride for InjectionDrug
Intravenous infusion.
Bevacizumab InjectionDrug
Intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China · Not yet recruiting
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China · Not yet recruiting
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Not yet recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
People's Hospital of Hunan Province
Changsha, Hunan, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Xi 'an International Medical Center Hospital
Xi’an, Shanxi, China · Not yet recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.